# Collaborations Between Pharma and Digital Health Startups: Advancing Innovation and **Reimbursement in Digital Health Technologies**

Divya Pushkarna, Ramandeep Kaur, Michael del Aguila, Mir Sohail Fazeli Evidinno Research Outcomes Inc., Vancouver, British Columbia, Canada

# Background

- Digital health technologies (DHTs) encompassing wearable devices, mobile health applications, telemedicine platforms, and electronic health records enhance health outcomes by enabling real-time health monitoring, early disease detection, and personalized treatment plans.<sup>1,2</sup>
- The global digital health market, valued at about US\$143 billion in 2022, is forecasted to grow at a robust compound annual growth rate of 25%, reaching US\$180 billion in 2023 and US\$550 billion by 2028.<sup>3</sup>
- Integrating DHTs in healthcare reduces administrative burdens, minimizes errors, and accelerates decision-making, improving care quality, lowering costs, and better adherence to treatment plans.<sup>2,4</sup>
- DHTs provide valuable data and insights that enhance research and development of more effective treatments.<sup>2</sup>
- DHTs help engage patients to enhance responsibility for self-care and discussing issues with HCP in context of shared decision making.<sup>4</sup>
- The growing importance of digital health has led to increased collaboration between digital health startups/companies and pharmaceutical firms. These partnerships allow pharmaceutical firms to integrate cutting-edge innovations into their pipelines more quickly and efficiently.<sup>5</sup>

# **Objective**

This study aimed to examine how pharmaceutical companies and digital health startups collaborate to develop DHT innovations and how these partnerships secure reimbursement.

# Methods

### **Data collection**

- ► A targeted literature review was conducted on December 22, 2024, to identify the most recent peer-reviewed journal articles and news publications from PubMed and Google Scholar.
- Search terms included keywords for "Digital health technologies", "digital therapeutics", and "pharma collaboration".

### Inclusion criteria

Documents published between 2016 and 2024 and in English language were identified for relevant case studies of collaborations between a pharmaceutical company and a DHT startup/company.

### Analytical framework

The review focused on describing industry insights and examples were incorporated analyzing the type of partnership, geography, type of intervention, therapeutic area(s), and key success factors.

# Results

- ► Fifteen collaborations were included, majorly from US (n=10) and three each from Europe and Australia, which secured approval and reimbursement for DHTs (**Table 1**), targeting different therapeutic areas.
- Common partnership models included joint ventures, sponsorship/ licensing, strategic investments, and building your own solution (Figure 1).
- These collaborations leveraged complementary strengths: pharmaceutical companies provided clinical trial infrastructure and market access, while startups contributed agility and technological innovation.
- Reimbursement challenges faced by DHTs included lack of standard value assessment criteria and uncertainties in trial design.
- These challenges were addressed by collaboratively developing roadmaps between the DHT startup/company and the pharmaceutical company to navigate the complex reimbursement landscape.<sup>6</sup>

# **Results (continued)**

Key success factors included goal alignment, shared intellectual property agreements, and early engagement with regulatory and reimbursement stakeholders. • Early payer collaboration and integration of health economic evidence proved critical for reimbursement, with clinically effective and cost-efficient technologies achieving greater success. Pharma companies can acquire ready-to-go solutions with approved indications and active user bases, gaining more control over strategy and direction. However, no case studies have shown

- successful reimbursement through this model yet.

# **Table 1:** Overview of DHTs included resulting from digital health company and pharma collaborations

Collaboration	Year	Country	Therapeutic Area	D
Bayer and One Drop <sup>7</sup>	2020	US	Diabetes	Ai dia
Novartis and Pear Therapeutics <sup>8</sup>	2018	US	Schizophrenia, multiple sclerosis	De dis
Pfizer and IBM Watson Health <sup>9</sup>	2018	US	Oncology research	Al an
Merck and Livongo <sup>10</sup>	2018	US	Several	Pr
Eli Lilly and Livongo <sup>11</sup>	2018	US	Diabetes	In co
Boehringer Ingelheim and Propeller Health <sup>12</sup>	2016	US, AUS	Asthma and COPD	Co Ing an
Brandon BioCatalyst, ANDHealth and Dementia Australia <sup>13,14</sup>	2024	AUS	Dementia and Cognitive Decline	Ai
Medtronic and DTx Companies <sup>15</sup>	2020- 2024	AUS	Chronic disease management	Pa dię
Sanofi and Babylon <sup>16</sup>	2020	UK	Gastrointestinal	Of
Chiesi Farmaceutici and Kaia Health <sup>17</sup>	2020	Germany	Chronic back pain and COPD	Br th
Bristol Myers Squibb (France) and Moovcare <sup>18</sup>	2020	France	Lung cancer	Re inv
Eli Lilly with Sidekick Health <sup>20</sup>	2022	Germany	Breast cancer	Im
Sanofi and DarioHealth <sup>19</sup>	2022	US	Diabetes	De
Sanofi and Happify Health <sup>21</sup>	2019	US	Mental health	In dis
Roche and Flatiron Health <sup>22</sup>	2018	US	Oncology research	Er da

AUS: Australia; COPD: Chronic obstructive pulmonary disorder; DTx: Digital therapeutics; RWE: Real world evidence; UK: United kingdom; US: United States 📃 Joint ventures 📃 Sponsorship/licensing 📃 Strategic investments 📃 Build your own solution

# Conclusions

- Partnerships between pharmaceutical companies and digital health startups combine technological innovation with established clinical expertise to create patient-centric solutions. These collaborations address reimbursement challenges, align strategic goals, and integrate economic evidence to drive healthcare improvements.
- The focus on diverse markets, including the US, Australia, and Europe, highlights the global impact and potential of these partnerships in advancing digital health innovations.

Acknowledgments

> This study was conducted by Evidinno Outcomes Research Inc. DP, RK, MdA, and MSF report employment with Evidinno Outcomes Research Inc. Authors report no other conflict of interest.

Several trends are likely to shape the future of partnerships between pharmaceutical companies such as increased use of artificial intelligence, expansion of digital therapeutics, focus on real-world evidence (RWE), emphasis on patient engagement, regulatory and compliance innovations, sustainability and value-based care.

### OHT developed

ms to integrate One Drop's digital platform with Bayer's expertise in betes care to provide comprehensive support for patients

velop novel prescription digital therapeutics designed to effectively treat sease and improve patient clinical outcomes

accelerating the discovery of new cancer treatments by analyzing vast mounts of clinical data

ovide personalized care and improve patient engagement

tegrates Livongo's digital tools with Eli Lilly's medications, providing a mprehensive solution for diabetes management

ombines Propeller's connected inhalers and mobile app with Boehringer gelheim's respiratory treatments, leading to improved patient adherence nd outcomes

im to accelerate the adoption of clinically validated DTx in Australia

Partnerships with various digital health startups to develop and implement gital therapeutics for chronic disease management.

offer access to an online gastrointestinal symptom checker

Bring patients a digital therapeutic that supports COPD treatment outcomes nrough behavior change, rather than relying on pharmacology

emote monitoring software for hospitals and healthcare professionals nvolved in lung cancer treatment in France.

prove the wellbeing of people being treated for breast cancer in Germany

velop digital solutions for diabetes management

egrating Happify's mental health solutions with Sanofi's expertise in sease management


nhance cancer research and treatment development through advanced ata analytics utilizing RWE for oncology from Flatiron

### References What is Digital Health? https://www.fda.gov/medical-devices/digital-health-center-excellence/what-digital-health What is digital health technology and what can it do for me? https://evidence.nihr.ac.uk/collection/what-is-digital-health-technology Digital Health Market: Growth, Size, Share, and Trends https://www.marketsandmarkets.com/Market-Reports/digital-health-market-45458752.html Digital Healthcare Transformation: Benefits, Challenges and Key Trends https://digitaldirections.com/digital-healthcare-transformation Evidera, Digital Therapeutics: Past Trends and Future Prospects, 2020 A long way to go" for digital health reimbursement https://deep-dive.pharmaphorum.com/magazine/market-access-2021/a-long-way-to-go-for-digital-health-reimbursemen Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis. https://www.novartis.com/news/media-releases/novartis-and-pear-therapeutics-develop-digital-therapeutics-patients-9. IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery https://www.pfizer.com/news/press-release/press-releasedetail/ibm\_and\_pfizer\_to\_accelerate\_immuno\_oncology\_research\_with\_watson\_for\_drug\_discovery 10. Livongo Health IPO: Funded By Merck And May Not Be Expensive At 10x Sales https://seekingalpha.com/article/4276056-livongo-health-ipo-funded-by-merck-and-may-not-be-expensive-at-10x-sales 11. Livongo and Lilly Collaborate on Real-World Diabetes Research https://investor.lilly.com/news-releases/news-release-details/livongo-and-lilly-collaborate-real-world-diabetes-research 13. CUREator+ Dementia and Cognitive Decline <a href="https://brandonbiocatalyst.com/cureator/cureator-plus-dementia-and-cognitive-decline">https://brandonbiocatalyst.com/cureator/cureator-plus-dementia-and-cognitive-decline</a> 14. Five promising digital health companies selected to scale new health technologies https://biotechdispatch.com.au/news/five-promising-digital-health-companies-selected-to-scale-new-he Australia's National Digital Health Strategy: Key Implications for the Pharmaceutical & Medical Technology Sector How Pharma and Medtech Industries Have Opportunities to Innovate to Align With New Digital Health Standards https://www.digivatehealth.com.au/insights/australias-national-digital-health-strategy-key-implications-for-the-pharmaceutical-amp-medical-technology-sector Sanofi announces three-month Babylon pilot to assist people with digestive health issues https://www.mobihealthnews.com/news/emea/sanofi-announces-three-month-babylon-pilot-assist-17. Kaia Health and Chiesi Group Announce Strategic Partnership to Commercialise Kaia COPD Pulmonary Rehabilitation App in European Markets https://www.chiesi.com/en/kaia-health-and-chiesi group-announce-strategic-partnership-to-commercialise-kaia-copd-pulmonary-rehabilitation-app-in-european-market 18. Moovcare, 1st app to achieve reimbursement in France. #mhealth #digitalhealth #cancer https://www.doctors20.com/moovcare-reimbursement-dr-fabrice-denis/ 19. Lilly partners with Sidekick in digital health alliance https://pharmaphorum.com/news/lilly-partners-with-sidekick-in-digital-health-alliance 20. DarioHealth Enters into Strategic Agreement with Sanofi U.S. <u>https://dariohealth.investorroom.com/2022-03-01-DarioHealth-Enters-into-Strategic-Agreement-with-Sanofi-U-S</u> 21. Happify Health and Sanofi Sign Global Agreement to Bring Prescription Digital Mental Health Therapeutics to Individuals with Multiple Sclerosis https://www.prod pify-health-and-sanofi-sign-global-agreement-to-bring-prescription-digital-mental-health-therapeutics-to-individuals-with-multiple-sclerosis-300918901.html Flatiron Health https://www.roche.com/innovation/structure/flatiron









HPR20



Figure 1: Common partnership models seen between digital companies and pharmaceutical collaborations

### Joint ventures

- Combines the complementary expertise of pharma and tech partners
- Usually faster as the technical platform and processes to support the DTx are often readily available; may include product approvals and an existing user base

## Sponsorship / Licensing a Solution

- A relatively fast and relatively low-cost entry into the DTx space
- It can work as a flexible short-term solution

# Strategic investments

- Forms strategic alliances for mutual benefits
- Offers co-promotion, product development and cocommercialization

Bayer and Informed Data Systems Inc. (One Drop) join forces to jointly develop digital health products across therapeutic areas https://www.bayer.com/media/en-us/bayer-and-informed-data-systems-inc-one-drop-join-forces-to-jointly-develop

12. Propeller Health and Boehringer Ingelheim Announce New Partnership Focused on Improving Adherence and Care Management for People Living with COPD and Asthma https://www.boehringer-ingelheim.com/us/propeller-health-bi-announce



Copies of this poster are for personal use only and may not be reproduced without written permission of the authors.